Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

35.63USD
19 Jan 2017
Change (% chg)

$-0.41 (-1.14%)
Prev Close
$36.04
Open
$35.72
Day's High
$35.82
Day's Low
$35.57
Volume
448,833
Avg. Vol
723,601
52-wk High
$57.81
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $72,634.28
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.45
Yield (%): 2.52

Financials

  NVO.N Industry Sector
P/E (TTM): 17.10 29.93 30.76
EPS (TTM): 2.11 -- --
ROI: 81.12 15.46 14.89
ROE: 88.79 16.64 16.30

European shares down, weighed by healthcare sector after Trump comments

* Europe's healthcare sector bruised by Trump drug prices barb

12 Jan 2017

UPDATE 1-Novo Nordisk shares hit by US lawsuit, Trump comments

* Novo shares down 5.4 pct while Europe drug stocks down 2 pct (Adds comments from Novo Nordisk, Trump and analyst, details)

12 Jan 2017

U.S. law firm files class action suit against Novo Nordisk

COPENHAGEN, Jan 12 A U.S. law firm has filed a securities class action lawsuit on behalf of Lehigh County Employees' Retirement System against Danish drugmaker Novo Nordisk.

12 Jan 2017

BRIEF-Novo Nordisk's Fiasp approved in Europe

* The European Commission has granted marketing authorisation for Fiasp (fast-acting insulin aspart) for treatment of diabetes in adults

10 Jan 2017

Sanofi sues Novo Nordisk over diabetes drugs in the U.S.

France's Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.

27 Dec 2016

Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

OSLO Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes.

05 Dec 2016

Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

30 Nov 2016

UPDATE 1-Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

30 Nov 2016

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed.

29 Nov 2016

UPDATE 1-TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

29 Nov 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €75.77 -0.73
Eli Lilly and Co (LLY.N) $76.84 -0.69

Earnings vs. Estimates